ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
ISAR-REACT 3 Pits Bivalirudin Vs. Unfractionated Heparin In PCI
A large randomized trial will shed
light on the ideal combination of medications for preventing unwanted blood
clotting during and shortly after percutaneous coronary intervention (PCI).
Specifically, study investigators expect to determine whether bivalirudin,
a direct inhibitor of the clotting protein thrombin, is better than
unfractionated heparin, an indirect thrombin inhibitor, in patients who
have also been treated with high-dose clopidogrel.
The Intracoronary Stenting and Antithrombotic Regimen: Rapid Early
Action for Coronary Treatment 3 (ISAR-REACT 3) study is being presented
today in a Late-Breaking Clinical Trials session at the SCAI Annual
Scientific Sessions in Partnership with ACC i2 Summit (SCAI-ACCi2) in
Chicago. SCAI-ACCi2 is a scientific meeting for practicing cardiovascular
interventionalists sponsored by the Society for Cardiovascular Angiography
and Interventions (SCAI) in partnership with the American College of
Cardiology (ACC).
Bivalirudin has outperformed unfractionated heparin in some previous
studies of PCI, but it's not clear how the two anti-clotting medications
measure up when used in combination with what has become standard protocol
in the cardiac catheterization laboratory: preloading with a 600-mg dose of
clopidogrel, a medication that prevents clotting by inhibiting platelets.
"The distinguishing feature of our study is that a double-blind
comparison of the two different anti-thrombotic regimens was performed
against a backdrop of optimal oral anti-platelet loading therapy," said
Adnan Kastrati, MD, a professor of cardiology and head of the
catheterization laboratory at Deutsches Herzzentrum and Technical
University, Munich, Germany. "We hypothesized that in patients who were
optimally pre-treated with clopidogrel, bivalirudin would continue to prove
superior to unfractionated heparin, at least in terms of safety -- by
reducing bleeding side effects."
Bivalirudin has several potential advantages over unfractionated
heparin: It does not rely on antithrombin to achieve its effects, it has a
more predictable dose-response pattern (and, therefore, does not require
routine blood test monitoring) and it has a short plasma half-life, which
is important if a patient develops a bleeding problem.
For the study, Dr. Kastrati and his fellow ISAR-REACT 3 investigators
recruited 4,570 low-to-intermediate-risk patients who were undergoing PCI
for reasons other than heart attack, randomly assigning them to receive
either unfractionated heparin or bivalirudin during the procedure. All
patients received 600 mg of clopidogrel at least two hours before PCI, and
all patients continued to take 75 mg of clopidogrel for at least one month
after balloon angioplasty or implantation of bare-metal stents, and for at
least six months after implantation of drug-eluting stents. Patients
continued to take aspirin indefinitely.
The study will determine whether use of bivalirudin influences rates of
bleeding during the initial hospitalization or the 30-day combined rates of
death, heart attack or urgent procedure to reopen the treated artery.
"This population under study is important, as it reflects the
predominant group undergoing PCI, perhaps up to 70 percent," said Dr.
Kastrati. "Our results may clarify the paradigm for peri-procedural
adjunctive therapy in this important group."
About SCAI
Headquartered in Washington, DC, the Society for Cardiovascular
Angiography and Interventions is a 4,000-member professional organization
representing invasive and interventional cardiologists in over 60 nations.
SCAI's mission is to promote excellence in invasive and interventional
cardiovascular medicine through physician education and representation, and
advancement of quality standards to enhance patient care. SCAI's annual
meeting has become the leading venue for education, discussion, and debate
about the latest developments in this dynamic medical specialty.
About ACC
The American College of Cardiology is leading the way to optimal
cardiovascular care and disease prevention. The College is a 34,000-member
nonprofit medical society and bestows the credential Fellow of the American
College of Cardiology upon physicians who meet its stringent
qualifications. The College is a leader in the formulation of health
policy, standards and guidelines, and is a staunch supporter of
cardiovascular research. The ACC provides professional education and
operates national registries for the measurement and improvement of quality
care.
ACC
http://www.acc.org
ISAR-reacþiona 3 Pits Bivalirudin Vs. Unfractionated heparina În PCI - ISAR-REACT 3 Pits Bivalirudin Vs. Unfractionated Heparin In PCI - articole medicale engleza - startsanatate